First Patients Treated in PRESERVE Clinical Study

Study Assessing Use of NanoKnife System in Prostate Tissue Ablation

Latham, New York, April 14, 2022 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, has announced the first patients treated in the PRESERVE Clinical Study.

PRESERVE (Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population) will evaluate the use of AngioDynamics’ NanoKnife System for ablation of prostate tissue as a focal therapy option for prostate cancer patients. The PRESERVE Study was initiated by AngioDynamics, Inc., in partnership with the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC).

“We are very proud to have treated the first patients in the PRESERVE study,” said Ranko Miocinovic, MD, Integrated Oncology Program, Urology Department at Duly Health and Care, who performed the first case. “We look forward to bringing this innovative treatment to more patients in our community.” A second PRESRVE Study case was performed by Amit Patel, MD, Chairman, Urology Department, Duly Health and Care, immediately following Dr. Miocinovic’s case.

“AngioDynamics is proud to work with partners in building new pathways for treatment of prostate cancer,” said Chad Campbell, General Manager and Senior Vice President, Oncology and Vascular Access, AngioDynamics. “We believe our NanoKnife System ablation platform provides a treatment option that can preserve function and quality of life in patients with prostate cancer. We thank Drs. Miocinovic and Patel, their team at Duly Health and Care, SUO-CTC, and our provider partners for their support on the PRESERVE Study.”

PRESERVE is led by Co-Principal Investigators Jonathan A. Coleman, MD, Urologist at Memorial Sloan Kettering Cancer Center, and Arvin George, MD, Urologist at the University of Michigan. The single-arm study will assess the safety and effectiveness of the NanoKnife device when used to ablate prostate tissue in intermediate-risk prostate cancer patients. The study’s primary objectives are determining the NanoKnife System’s ablation effectiveness by measuring the negative in-field biopsy rate at 12 months and determining the NanoKnife System’s procedural and post-procedural safety profile by evaluating adverse event incidence, type, and severity through 12 months. The study is expected to conclude by March 2024 and enroll 118 patients in facilities across the United States. Learn more about PRESERVE at

About the NanoKnife System

The NanoKnife System utilizes Irreversible Electroporation (IRE) technology to effectively destroy targeted cells without the use of thermal energy by delivering high-voltage pulses, creating permanent nanopores within the cell membrane. This stimulus induces an apoptotic-like cellular death in the targeted tissue, resulting in a complete ablation of the targeted tissue. Visit for full product information. Visit for risk information. The NanoKnife System has been cleared by the FDA for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition.

About AngioDynamics

AngioDynamics is a leading, and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit

About Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC)

Created, owned and operated by its members, the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC) is a clinical research investigator network of more than 400 members from more than 200 clinical sites in the U.S. and Canada. This national alliance of leading academic and community based uro-oncologists is committed to furthering urology research. The SUO-CTC is a registered 501c3 not-for-profit corporation and has a cooperative relationship with the Society of Urologic Oncology (SUO). For more information, visit

AngioDynamics, the AngioDynamics logo, and NanoKnife are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners.

Investor Relations Contact:

Stephen Trowbridge

Media Contact:

Saleem Cheeks